US › Healthcare

Dogwood Therapeutics, Inc. (DWTX)

US · Healthcare · Biotechnology

$1.79+4.68%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.0M
Profit YoY
+54.4%
EPS
$-0.15
EPS estimate
$-0.20

EPS came in at -0.15 against a street estimate of -0.20 — a beat of 25.0%.

Key statistics

Market cap
$57.5M
P/E
1.5
Forward P/E
0.0
P/B
0.68
Book value
$2.41
EPS (TTM)
$1.17
52-week high
$9.50
52-week low
$1.28
50-day MA
$1.55
200-day MA
$3.17
Beta
1.76

Analyst view

Analysts rate Dogwood Therapeutics, Inc. a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $14.00.

Shareholding

Insiders
73.35%
Institutions
10.97%

Largest institutional holders

FundStake
Armistice Capital, LLC9.75%
Vanguard Capital Management, LLC0.39%
Geode Capital Management, LLC0.24%
Vanguard Fiduciary Trust Co0.19%
Vanguard Group Inc0.09%
Northern Trust Corp0.07%
The Goldman Sachs Group Inc0.04%
Marshall Wace Asset Management Ltd0.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Dogwood Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.